|
M r.' 'an A~Mrff jRuasgl~Wr Mpuntr sf Hartehrn roadr~Ksyesiskr w g r paid a happy surprisa v l t llBt-wee 1 a r e the" service, Russell Wi Msunt, Jr"5, seaman eeesnd class, USNR, w h s h just finished hia boot t r a Baaapgen, NfW York, stepped off a t PSainfield t s ee his brother Don aid a n d sister, M r i . Eleanor Blomgren T h e followihgf day he "ivent to Brooklyn to eee his brotheri Du Mont Mount i e a second elass f USNR, and K e n -C, M o u n sift.
The following ingredients: procaine penicillin, benzathine penicillin, are mentioned in the susdp.
The Detection System Immediately after planar imaging, single-photon ECT of the myocardium with 201T1 was performed. The ECT used in this study consisted of a large-fieldof-view gamma camera and a high-resolution, parallel-hole collimator on a tunnel-figured gantry Maxi 400-T, GE ; , which rotated 3600 around the body of the patient, collecting data from 64 views. Data collection required 22 minutes for myocardial imaging. The data were reconstructed into 12-mm-thick multiple slices in transaxial planes by a filtered back-projection method with Chesler's filter 6 using a convolution reconstruction algorithm.27 It took the computer PDP 11, DEC.
ACUTE STUDIES: SENSITIZATION: Penicillins are a sensitizing agent. Hypersensitivity reactions are frequently reported. Dihydrostreptomycin sulfate may cause skin sensitization. INTRAVENOUS LD50 RAT ; : 97 mg kg penicillin G procaine ; . ORAL LD50 MOUSE ; : 2 g penicillin G procaine 600 mg kg dihydrostreptomycin sulfate ; . INTRAPERITONEAL LD50 MOUSE ; : 146 mg kg penicillin G procaine 1, 380 mg kg dihydrostreptomycin sulfate ; . SUBCUTANEOUS LD50 RAT ; : 6 g penicillin G procaine 1, 100 mg kg dihydrostreptomycin sulfate ; . SUBCUTANEOUS LD50 MOUSE ; : 2, 300 mg kg penicillin G procaine 761 mg kg dihydrostreptomycin sulfate ; . OTHER STUDIES: CARCINOGENICITY: Ingredient s ; are not listed as carcinogenic by IARC, NTP or OSHA. This drug is subject to FDA labeling requirements; therefore, it is exempt from the labeling requirements of the OSHA Hazard Communication Standard. NDC 0009-3267-02.
This patient falls into a subcategory of idiopathic hypogonadotropic hypogonadism with isolated LH deficiency and normal FSH--this is known as fertile eunuch syndrome. In this group of patients stimulation with hCG often stimulates adequate maturation of Leydig cells, and the patients' requirements for hCG may be much lower. FSH is sometimes added in those men if FSH is low although it seems in this patient it is not really indicated because he had normal FSH. I assume that his TSH, cortisol, and iron studies are normal and his MRI is negative--craniopharyngioma and microadenoma. The fact that he had sperm on testicular biopsy and azoospermia in ejaculated semen indicates obstructive azoospermia. Based on wife's age, IVF with testicular sperm is an adequate choice. One could consider holding off on hCG and FSH and repeating them together with testosterone in 6 weeks. If his LH and FSH are normal and testosterone within normal limit for an age-adjusted group, no further treatment is needed. An interesting aspect of fertile eunuch syndrome is the presence of sperm despite low circulating testosterone. This is most likely related to an adequate concentration of testosterone within testis to maintain qualitative spermatogenesis but not enough production for normal peripheral testosterone. Those men produce small amounts of LH often too low to measure using current assays otherwise they would not go through puberty. Of note, 5000 units of hCG is a dose used for diagnostic stimulation and not typically used for treatment anymore. Recent literature supports using much lower doses of hCG, even 500 units subcutaneously every other day. The main concern comes from studies in animals that showed that excess of hCG may create a chronic inflammatory-like response in the interstitium.
Recurred. The ANA titers did not rise in any of these nine patients. Three patients without symptoms voluntarily discontinued the drug during the first 3 months. One man died suddenly 6 weeks postinfarction while on therapy. Late reactions were observed in 14 of patients who took procaine amide for 3 months or longer. Of these, 12 had arthralgia and or rash, one had headaches, and another marked fatigue. Four patients without symptoms voluntarily stopped the medication after 6-22 months of therapy. Eight patients continued to take procaine amide for 18-30 months without adverse effects table 1 and procarbazine!
Figure 9. The structure of the procaine benzylpenicillin salt. The benzylpenicillin is shown above and the procaine below. Procaine benzylpenicillin has low water solubility. If procaine is exchanged by sodium Na + ; or potassium K + ; the more water-soluble Na K benzylpenicillin salts are formed.
PENICILLIN G PREPARATIONS--PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE No Bicillin C-R, Bicillin C-R 900 300 Antibiotic, penicillin very long acting ; Bicillin CR: 150, 000 U PenG procaine + 150, 000 U PenG benzathine mL to provide 300, 000 U penicillin per 1 mL 10 vial ; 300, 000 U PenG procaine + 300, 000 U PenG benzathine mL to provide 600, 000 U penicillin per 1 mL 1, 2 tubex, 4 mL syringe ; Bicillin CR 900 300 ; : 150, 000 U PenG procaine + 450, 000 U PenG benzathine mL 2 mL tubex ; All preparations contain parabens and povidone. Injection should be for IM use only and procrit.
Free Procaine
Late Latent: benzathine penicillin 37.5 mg kg to 1.8 g i.m. once weekly for 3 w, procaine penicillin 1 g i.m. once daily for 15 d Penicillin Hypersensitive: consider desensitisation; doxycycline 100 mg orally 12 hourly for 28 d not pregnant or breastfeeding ; Tertiary: benzylpenicillin 1.8 g i.v. 4 hourly for 15 d Cardiovascular Syphilis, Neurosyphilis: + prednisolone or prednisone 20 mg orally 12 hourly for 3 doses Follow-up: Primary: serology every 3 mo for 1 y Secondary, Latent and Late: serology every 3 mo for 1 y, then at 18 and 24 mo Prophylaxis Exposure 30 d ; : procaine benzylpenicillin 2.4-4.8 MU i.m., ceftriaxone 125 mg single dose Prevention and Control: exposure prevention, identification and treatment of cases CONGENITAL SYPHILIS: see Chapter 5 NONVENEREAL SYPHILIS BEJEL EUPHRATES VALLEY ; , DICHUCHWA BOTSWANA ; , ENDEMIC SYPHILIS, ENDEMIC SYPHILIS OF THE BEDOUINS, NJOVERA ZIMBABWE ; , SITI GAMBIA, SENEGAL ; , SKERLJEVO OR SKRLEVO BOSNIAHERZEGOVINA, MACEDONIA AGENT: Treponema pallidum biotype endemicum Diagnosis: similar to ACQUIRED SYPHILIS except primary stage often passes unnoticed and more serious late manifestations are rare; all serological tests for syphilis positive; differential diagnosis from acquired syphilis only possible within epidemiological setting Treatment: as for ACQUIRED SYPHILIS CHANCROID CHANCRELLE, CHANCRE MOU, CHANCRE SIMPLEX, DUCREY CHANCRE, DUCREY DISEASE, GENITAL ULCER, SIMPLE CHANCRE, SOFT CHANCRE, SOFT SORE, ULCUS MOLLE ; : worldwide; acute, sexually transmitted infectious disease of the genitalia; people infectious as long as they have ulcers; no transmission from mother to foetus or during delivery; rare cases in Australia; ? 700 cases y in USA; incubation period 1-10 d usually 3-7 d found in 15% of primary syphilitic chancres and 28% of patients with herpes genitalis Agent: Haemophilus ducreyi Diagnosis: women may have no symptoms; 1 or more painful pustular lesions, at entrance to vagina and around anus in women and on penis in men, that may rupture to form suppurative ulcers; women may have pain on urination or defecation, rectal bleeding, pain on intercourse or vaginal discharge; regional lymphadenopathy inguinal adenitis with softening appearing after 7-10 d ; in up to cases; microscopy characteristic arrangement of bacteria ; and culture high humidity at 33-35? C on enriched gonococcal agar + 1% bovine haemoglobin + 5% serum and on Muller-Hinton agar + 5% chocolatised horse blood, repeating culture on first medium at 48 h ; swab of lesion or aspirate from flocculant node sensitivity 92%; negative cultures 38% prior medication, 38% syphilis, others ? occasionally, a biopsy may be required; tests for syphilis and herpes simplex virus negative Treatment Patients and Sexual Partners ; : ulcers disappear without treatment usually in about a month but may last up to 12 w; azithromycin 1 g orally as single dose not in pregnant or breastfeeding ; , ceftriaxone 250 mg i.m. as a single dose, ciprofloxacin 500 mg twice a day orally for 3 d not in pregnant or lactating women ; , erythromycin 500 mg orally 8 hourly for 7 d, cotrimoxazole 160 800 mg orally 12 hourly for minimum 10 d, tetracycline 500 mg orally 6 hourly for 14-21 d, sulphisoxazole 1 g orally 6 hourly for 10 d, amoxycillin-clavulanate 500 125 mg 8 hourly for 7 d, rosoxacin 450 mg 12 hourly orally for 3 d; reexamine 3-7 d after initiation of therapy; incision and drainage of buboes if required Prevention and Control: exposure prevention GENITAL HERPES: 5% of sexually transmitted disease in male, 4% in female; 0.2-0.5 M cases y in USA 20% seroprevalence in 12 y old; 30% increase in past decade 10% incidence in homosexuals; 30 100 000 physician' visits; s 17% of women and 4% of men infected when living with infected partner for median 344 d; 90% of persons with genital herpes simplex 2 shed virus asymptomatically; incubation period 1-26 d average 6-7 d ; Agent: herpes simplex up to 30% type 1 recurrences much less frequent ; , remainder type 2 ; Diagnosis: 60% unrecognised with symptoms, 20% recognised genital herpes, 20% truly asymptomatic; painful, multiple, blisterlike, ulcerating lesions in and around vagina, around anus or on thighs in women or on penis in men; can cause vulval perianal fissures, internal lesions, reddening on buttocks thighs, painful urination, vaginal urethral discharge, aching lower limbs, headache, radicular or lower back pain, fever, malaise, stiff neck, abnormal sensitivity to light; may mimic cystitis, candidiasis or prostatitis; can lead to cervicitis and proctitis; of those infected have recurrences, involving smaller and fewer lesions and less severe systemic reactions, though pain, numbness or tingling in buttocks, legs or hips may precede outbreak; immunofluorescence, viral culture Cellmatics? mink lung cells most useful cell line for.
AAC Doc.# 084-0521, Corin, Tampa, FL An inspection of this sponsor, conducted August 5, 2005, revealed serious deviations from 21 CFR Parts 812 and 50. The following observations were noted: there was shipment, delivery, and receipt of adulterated and misbranded devices in interstate commerce; failure to control investigational devices; failure to ensure adequate monitoring of an investigational study; and failure to submit complete, accurate, and timely reports of unanticipated adverse effects to the reviewing IRB and FDA. Date: 11 22 2005 Page s ; : 6 AAC Doc.# 084-0522 Institutional Review Board, Baltimore, MD An inspection of the Baltimore City Health Department Institutional Review Board conducted from August 22 through 29, 2005, revealed significant deviations from 21 CFR Parts 50 and 56. The following was noted: the IRB failed to follow its written procedures for conducting the review of research; the IRB failed to prepare and maintain adequate documentation of IRB activities; and the IRB failed to review proposed research at convened meetings at which a majority of the members of the IRB were present. Date: 12 15 2005 Page s ; : 6 calf was sold for slaughter as human food with levels of neomycin in the kidney tissue, even though neomycin is not approved for use in veal calves; lack of an adequate system to ensure that animals medicated have been withheld from slaughter for appropriate periods of time to permit depletion of potentially hazardous drugs from edible tissues; and failure to use the drug Neomycin 325 Soluble Powder in conformance with its approved labeling. Date: 12 8 2005 Page s ; : 2 AAC Doc.# 085-6138 Morrell Farm, Franklin, NY An investigation of this dairy farm operation conducted on August 11 and 18, 2005, confirmed that an animal was offered for sale for slaughter as food that was adulterated under sections 402 a ; 2 ; C ; and 402 a ; 4 ; of the FD&C Act. It was also revealed that the new animal drug, Pen-Aqueous Penicillin G Procaine Injectable Suspension, was caused to be adulterated within the meaning of Section 501 a ; 5 ; and unsafe under section 512 of the Act. The following was noted: the presence of the drug penicillin was found in the edible tissues of the animal at levels above the established tolerance; animals were held under conditions so inadequate that medicated animals bearing potentially harmful drug residues were likely to enter the food supply; and the extralabel use of the drug, Pen-Aqueous Penicillin G Procaine Injectable Date: 12 2005 Page s ; : 2 and prohibit.
Birds receiving 10 mg of aureomycin at the time of exposure and again 24 hours later died. One pigeon out of four treated with 5, 000 units of procaine penicillin died. The organism was not recovered from the liver. Three out of five birds receiving 10, 000 units at the time of exposure died. One bird of five treated with 10, 000 units at the time of exposure and 24 hours later died, but the organism was not recovered. In all cases untreated controls died.
| Buy cheap Procaine onlineThere was no intergroup difference in the duration of the ECC, aortic cross-clamping time, or the number of grafts Table 1 ; . At the time of declamping of the aorta there was no significant difference between the two groups procaine control with regard to rectal temperature 32.7"C + 0.3 [range, 29.8-36.6] 32.2"C t 0.2 [range, 29.5-33.011, mean arterial pressure 44 mm Hg -t 2.2 [range, 15-66] 47 mm Hg t 2.4 [range, 25-7511, or pump flow 4.0 L min + - 0.1 [range, 2.55.01 3.8 + - 0.2 [range, 2.3-5.01 ; . The serum potassium level may influence the rhythmic stability but there was no intergroup difference at the time of declamping 4.2 mM t 0.1 [range, 3.5-5.71 4.1 mM + 0.1 [range, 3.0-5.71 for procaine control ; . The rhythmic stability was markedly different between the groups after the release of the aortic crossclamp Fig. 2, 3; Table 2 ; . In some casesVF was difficult to convert to stable rhythm and consequently lidocaine was used more frequently in the control group. Several patients in the control group having obtained stable rhythm by DC shock, relapsed to VF and were treated repeatedly by electroconvertion. The procaine group was characterized by postischemic asystole that lasted for l-5 min after declamping; then they started in a stable rhythm as shown in Figures 2 and 3. Sinus rhythm was regained in most of the patients in both groups within 20-30 min Fig. 3 ; . Synchronized DC shock was administered if sinus rhythm was not obtained at the time of weaning from ECC, and this was used more frequently in the control group P 0.05 ; . There was a tendency that the time from declamping until weaning from ECC was less in the procaine group P 0.06; Table 1 ; . One patient procaine group ; was reoperated 1.5 h after arrival in the intensive care unit because of increasing hemorrhage. Bleeding from the mammary artery stalk was found. One patient control group ; was reoperated after a 4-h intensive care unit stay. No specific cause for bleeding was found. The postoperative course was otherwise uneventful for these two patients. Bleeding and transfusion requirements were moderate and not different between the groups. The hemoglobin on the first morning after surgery was 97 g L 1.9 range, 77-117 ; and 101 g L 2 1.9 range, 81-116 ; procaine control ; . During the hospital stay a total of 20% 23% of the patients received transfusion procaine control ; . The intubation time was 255 min ? 41 range, 30-720 ; and 237 min 2 25 range, 30-520 ; in the two groups procaine control; not significant [NSI ; . Four hours after surgery the FIO, was 0.55 + 0.03 range, 0.3-1.0 ; 0.48 2 range, 0.3-0.7 ; procaine control, NS ; . There was no intergroup difference in postoperative fluid balance and the weight gain the first morning after surgery was 2.8 kg f. 0.3 range, 0.6-5.4 ; and 2.5 kg ? 0.2 range, 0.1-4.4 ; for the two groups NS ; . The enzyme release the first and prolixin.
In post-race analysis of urine, it is impossible to distinguish between legitimate therapeutic use of procaine penicillin and other uses of this agent.
Exercise unless other arrangements acceptable to the Company are made with respect to the satisfaction of such withholding obligations ; . d ; Payment of Exercise Price . The purchase price of shares of Common Stock acquired pursuant to the exercise of an option granted under the Plan may be paid in cash, certified or bank check, and or such other form of payment as may be permitted by the Committee from time to time, including, without limitation, shares of Common Stock which, if acquired from the Company, have been owned by the optionee free and clear of any liens or encumbrances ; for at least six months or, if the Common Stock is publicly-traded, pursuant to a cashless exercise procedure established by the Company in accordance with Regulation T of the Federal Reserve Board. e ; Rights as a Stockholder . No shares of Common Stock will be issued in respect of the exercise of an option granted under the Plan until full payment therefore has been made and the applicable tax withholding obligation has been satisfied or provided for, which withholding obligation, if satisfied with shares of Common Stock subject to an option being exercised, shall not exceed the statutory minimum rate. The holder of an option will have no rights as a stockholder with respect to any shares covered by an option until the date a stock certificate for such shares is issued to him or her. Except as otherwise provided herein, no adjustments shall be made for dividends or distributions of other rights for which the record date is prior to the date such stock certificate is issued. Nontransferability of Options . No option granted under the Plan may be assigned or transferred except by will or by the f ; applicable laws of descent and distribution; and each such option may be exercised during the optionee's lifetime only by the optionee. Notwithstanding the preceding sentence, the Committee may, in its sole discretion, permit an optionee to transfer an option other than an Incentive Stock Option ; , in whole or in part, to such persons and or entities as are approved by the Committee from time to time and subject to such terms and conditions as the Committee may determine from time to time. g ; Termination of Em ployment or Other Service . Except as otherwise provided herein or determined by the Committee, the following rules will apply with regard to options held by an optionee at the time of his or her termination of employment or other service with the Company and its affiliates: 1 ; Termination due to Death or Disability . If an optionee's employment or other service terminates due to his or her death or Disability or if the optionee's employment or other service is terminated by reason of his or her Disability and the optionee dies within one year of such termination of employment or other service ; , then: A ; that portion of an option that is not exercisable on the date of termination will immediately terminate, and B ; that portion of an option that is exercisable on the date of termination will remain exercisable, to the extent exercisable on the date of termination, by the optionee or the optionee's designated beneficiary or representative ; during the one year period following the date of termination or, during the one year period after the later death of a disabled optionee ; or, if sooner, until the expiration of the stated term thereof, and, to the extent not exercised during such period, will thereupon terminate. For purposes hereof, unless otherwise determined by the Committee, the term "Disability" means the inability of an optionee to perform the customary duties of his or her 3 and propantheline.
|
Oxtriphylline Oxybenzone Oxybutynin Chloride Oxybutynin Related Compound A Limit test Formerly Cat. No. 53180-1 ; Oxycodone Controlled Substance CII Oxycodone HCl Controlled Substance CII * Discontinued Item - No Longer Required * Oxymetazoline HCl Oxymetholone Controlled Substance CIII Oxymorphone Controlled Substance CII Oxyphenbutazone Oxyquinoline Sulfate Oxytetracycline Oxytocin 46 USP units per vial ; Padimate O Palmitic Acid Pamoic Acid Pancreatin [Effective 5 15 95 Please order Cat. No. USP49405-7, USP Pancreatin Amylase and Protease Ref. Std. 2 g ; and or Cat. No. USP49407-9, USP Pancreatin Lipase Ref. Std. 2 g ; ] Pancreatin Amylase and Protease Pancreatin Lipase Racemic Panthenol Pantolactone Limit test Papain Papaverine HCl Paramethadione Paramethasone Acetate Pargyline HCl Paromomycin Sulfate Particle Count Set, 2 blanks and 2 suspensions ; Penbutolol Sulfate Penicillamine Penicillamine Disulphide Limit test Penicillin G Benzathine For Identification Use Only. For Potency Use Cat. No. 50250-8 ; Penicillin G Potassium Penicillin G Procaine For Identification Use Only. For Potency Use Cat. No. 50250-8 ; Penicillin G Sodium For Identification Use Only. For Potency Use Cat. No. 50250-8 ; Penicillin V For Identification Use Only. For Potency Use Cat. No. 50450-3 ; Penicillin V Potassium Pentazocine Controlled Substance CIV Pentetic Acid Pentobarbital Controlled Substance CII Pentolinium Tartrate Pepsin Perflubron Perphenazine Perphenazine Sulfoxide Limit test Phenacemide Phenacetin Authentic Substance ; Phenacetin Melting Point Standard Approximately 135 ; Phenazopyridine HCl Phencyclidine HCl, Controlled Substance CII Authentic Substance ; Phendimetrazine Tartrate Controlled Substance CIII Phenelzine Sulfate D-Phenethicillin Potassium Limit test L-Phenethicillin Potassium Phenformin HCl.
The Essential Small Pharmacy Scheme ended in March 2006 when most existing ESPS pharmacies converted to the Essential Small Pharmacy LPS contract. This transfer was available as of right to every ESPS pharmacy that applied by the 31 October 2005 deadline, provided that the ESPS criteria on dispensing volume and distance to the nearest pharmacy was met. If an ESPS pharmacy was a special consideration case dispensing below 6000 items per year ; , then these could also transfer subject to the PCT certifying that the special circumstances had not changed. A very small number of ESPS pharmacies did not transfer to ESP LPS either because an application was not made, or the PCTs did not continue the `special consideration' status. These pharmacies remained within the ESPS arrangements. The ESPS arrangements had a 12 month period during which the payments would continue, but this period ends on 31 March 2007. Any pharmacies still operating under the original ESPS arrangements need to discuss with their PCTs any mechanisms for support from 1 April 2007. Examples of support may include maximising the commissioning of Enhanced Services, or could involve transfer to an LPS if there are any benefits to meeting local needs with innovative services and propylthiouracil.
Nursing Care of Patients with Upper Respiratory Tract Disorders 428 Paula D. Hopper and procaine.
Of the differentiated progeny to oxidative stress, as defined by their lower accumulation of reactive oxygen species such as peroxide, was also found. This implies that the differentiated cells derived from mTert overexpressing embryonic stem cells have a different redox state to the wild type. However there is no obvious difference in their ability to differentiate into various somatic cell types. We conclude that the decrease in stress resistance capacity, which occurs on differentiation of ES cells, represents a lower investment in damage repair. Reducing the activities of energetically expensive biochemical systems thus occurs in the developing body or 'soma' of an organism and protopic.
They have recommended the routine injection of 5-10 ml. of i per cent procaine into the extremity artery at the puncture site immediately prior to removal of the arterial catheter or cannula. Using this method, in a continued series of 215 arteniographies.
Ach issue of Choices has featured a personal experience with breast cancer, usually a narrative. Through these photos, Sheryl Sinkow graciously shows us part of her experience during the year of her diagnosis and treatment. In 1995, at age forty, Sheryl was told she had breast cancer. After a biopsy followed by a lymph node dissection and lumpectomy, a second form of breast cancer was discovered. Sheryl then underwent a bilateral mastectomy with immediate reconstructive surgery. She chose not to have chemotherapy. Photography, along with the encouragement and support of many people, sustained her and carried her through the horror, pain, and turmoil of that year. Sheryl has lived in Ithaca for thirteen years. Photography was a hobby while Sheryl studied anthropology at Berkeley and during her early adulthood. After moving to Ithaca, she established her photography business and protriptyline.
Probably, you have had some dental work made possible by a stiff shot of procaine to prevent pain and procarbazine.
Procaine ointment
11. WHICH OF THE BELOW IS NOT TRUE CONCERNING DISEASES OF THE GENITOURINARY TRACT? A. FORCE FLUIDS TO MAINTAIN URINARY OUTPUT OF 2-3 LITERS PER DAY FOR PYELONEPHRITIS B. INFILTRATION OF THE SPERMATIC CORD WITH PROCAINE HYDROCHLORIDE IS SOMETIMES USED TO TREAT EPIDIDYMITIS C. ANTISPASMODICS SHOULD NOT BE USED TO TREAT RENAL CALCULI D. THE PROSTRATE SHOULD BE MASSAGED IN A PATIENT WITH PROSTATITIS 12. WHAT CONDITION IS CAUSED BY BLOCKAGE OF ONE OR MORE OF THE BRANCHES OF THE CORONARY ARTERIES? A. B. C. ATHEROSCLEROSIS CONGESTIVE HEART FAILURE MYOCARDIAL INFARCTION ANGINA PECTORIS and provigil.
CIRS How to Respond to Chemical Incidents, Tuesday 21 May 2002 for all Public Health Consultants, Specialist Registrars, Nurses and Professionals who are on call . This one day course is an introduction to chemical incident response. Topics covered include a review of recent chemical incidents, how to respond to chemical incidents and lessons learnt, decontamination, exercises and information available from CIRS and the Medical Toxicology Unit. A maximum of 12 places are still available. CIRS Food Training Day, Thursday 20 June 2002 for CsCDC, Public Health Consultants, Specialist Registrars, Nurses and Professionals and Local Authority Environmental Health Practitioners. This one day course is designed to consider CIRS and CDSC Surveillance, the role of the Food Standards Agency in responding to chemical incidents, Local Authorities role in investigating chemically related food incidents, and Scrombotoxin and other nasties. A maximum of 20 places are available for this course. CIRS Update on Environmental Law Thursday 18 July 2002 for all Public Health Consultants, Specialist Registrars, Nurses and Professionals on call, Directors of Public health of Primary Care Trusts and Local Authority professionals This one day course is designed to provide an update in environmental law. The day will concentrate on problems reported to CIRS by public health professionals and will include issues relating to potentially exposed individuals who refuse decontamination to planning issues about proximity of housing to landfill sites. In addition it is proposed to review the implications of `class actions' and new legislation from the European Community. A maximum of 30 places are available for this course. CIRS Environmental Management Training Day. Thursday 19 September 2002 for CsCDC, Public Health Consultants, Specialist Registrars, Nurses and Professionals on call and Local Authority Environmental Health Practitioners This one day course is an introduction to environmental management of chemical incident response. Topics covered include a review of recent chemical incidents, which environmental issues to consider in response to chemical incidents and lessons learnt, with the related environmental issues such as sampling strategies, exercises and information available from CIRS. A maximum of 40 places are available for this course. CIRS How to Respond to Chemical Incidents, Thursday 17 October 2002, for all on call Public Health Consultants, Specialist Registrars, Nurses and Professionals This one day course is an introduction to chemical incident response. Topics covered include a review of recent chemical incidents, how to respond to chemical incidents and lessons learnt, decontamination, exercises and information available from CIRS and the Medical Toxicology Unit. A maximum of 40 places are available for this course. Waste Management Training Day, Thursday 21 November 2002 for Public Health Professionals Managers and Local Authority Environmental Health Practitioners ; This one day course is an introduction to waste management.
|
